Hepatitis A and B screening and vaccination rates among patients with chronic liver disease

被引:3
作者
Ramirez, Jonathan C. [1 ]
Ackerman, Kimberly [1 ]
Strain, Sasha C. [1 ]
Ahmed, Syed T. [1 ]
de los Santos, Mario J. [1 ]
Sears, Dawn [1 ]
机构
[1] Baylor Scott & White Healthcare, Gastroenterol, Temple, TX USA
关键词
chronic liver disease; hepatitis A virus (HAV); hepatitis B virus (HBV); vaccination; ADVISORY-COMMITTEE; VIRUS-INFECTION; IMMUNIZATION; IMMUNOGENICITY; RECOMMENDATIONS; CARE;
D O I
10.1080/21645515.2015.1068484
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Vaccinations against hepatitis A virus (HAV) and hepatitis B virus (HBV) are recommended for patients with chronic liver disease (CLD), yet implementation of these recommendations is lacking. This study reviewed HAV and HBV antibody testing and vaccination status of patients with CLD. In 2008, we began using pre-printed liver order sets, which included vaccination options. We compared Scott & White liver clinic CLD patient records from 2005 (238) with patient records from 2008 (792). Screening rates for immunity and vaccination rates of those lacking immunity were calculated. In 2005, 66% of CLD patients were screened for HAV immunity. In 2008, 56% of CLD patients were screened. The HAV vaccination completion rate was 37% in 2005, while in 2008, the rate was 46%. In 2005, 66% of CLD patients were screened for HBV immunity; in 2008, 56 % CLD patients were screened. The HBV vaccination completion rate was 26% in 2005 compared with 36% in 2008. Although there was a lower percentage of screening in 2008, the overall number of patients tripled between 2005 and 2008. There was a significant increase in the total number of patients screened and vaccinated in 2008. Some physicians may have vaccinated their patients without checking for immunity. In January 2008, we implemented pre-printed order sets with checkboxes to help remind providers to order labs to screen for immunity against HAV and HBV and to order vaccinations for those who lacked immunity. The use of these sets may have aided in the increase of vaccination completion rates.
引用
收藏
页码:64 / 69
页数:6
相关论文
共 14 条
[1]  
[Anonymous], 2015, REC AD IMM SCHED US
[2]   Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients [J].
Arguedas, MR ;
Johnson, A ;
Eloubeidi, MA ;
Fallon, MB .
HEPATOLOGY, 2001, 34 (01) :28-31
[3]  
Kochanek Kenneth D, 2011, Natl Vital Stat Rep, V60, P1
[4]  
Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P1
[5]  
Dumot JA, 1999, AM J GASTROENTEROL, V94, P1601, DOI 10.1111/j.1572-0241.1999.01150.x
[6]  
Duncan M, 2002, AM J GASTROENTEROL, V97, P1792, DOI 10.1111/j.1572-0241.2002.05844.x
[7]   Immunization needs of chronic liver disease patients seen in primary care versus specialist settings [J].
Jacobs, RJ ;
Meyerhoff, AS ;
Saab, S .
DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (08) :1525-1531
[8]  
KEEFFE EB, 1995, AM J GASTROENTEROL, V90, P201
[9]   Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease [J].
Keeffe, EB ;
Iwarson, S ;
McMahon, BJ ;
Lindsay, KL ;
Koff, RS ;
Manns, M ;
Baumgarten, R ;
Wiese, M ;
Fourneau, M ;
Safary, A ;
Clemens, R ;
Krause, DS .
HEPATOLOGY, 1998, 27 (03) :881-886
[10]  
Mast Eric E., 2005, Morbidity and Mortality Weekly Report, V54, P1